Sylvie Girard1, Guillaume Sebire2,3. 1. Department of Obstetrics and Gynecology, Sainte-Justine Hospital Research Center, University of Montreal, Montreal, QC, Canada. 2. Department of Pediatrics and Department of Neurology and Neurosurgery, McGill University Health Centre, McGill University, Montreal, QC, Canada. 3. Department of Pediatric, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC, Canada.
Abstract
PROBLEM: Prenatal exposure to inflammation increases the incidence of neonatal brain injury. This raise the question whether maternally produced cytokines, especially interleukin (IL)-1 elevated in pathological pregnancies and known to alter fetal development, can cross the placental barrier and affect the fetus directly. METHOD OF STUDY: We addressed if IL-1 agonist/antagonist could cross the placenta. RESULTS: Radiolabelled-IL-1 injected maternally reached the fetus in minimal amount. 3% of the amount detected within the placenta was transferred into the fetal liver and less than 1% recovered in the fetal brain 30 min after the injection Importantly, transfer of IL-1 was not affected by maternal exposure to LPS. Maternal administration of IL-1 receptor antagonist also reached the fetus in low concentration. CONCLUSIONS: This suggests that minimal amount of maternally produced IL-1 family members cross the placental barrier. Their negative effects are likely indirect, through their deleterious placental actions.
PROBLEM: Prenatal exposure to inflammation increases the incidence of neonatal brain injury. This raise the question whether maternally produced cytokines, especially interleukin (IL)-1 elevated in pathological pregnancies and known to alter fetal development, can cross the placental barrier and affect the fetus directly. METHOD OF STUDY: We addressed if IL-1 agonist/antagonist could cross the placenta. RESULTS: Radiolabelled-IL-1 injected maternally reached the fetus in minimal amount. 3% of the amount detected within the placenta was transferred into the fetal liver and less than 1% recovered in the fetal brain 30 min after the injection Importantly, transfer of IL-1 was not affected by maternal exposure to LPS. Maternal administration of IL-1 receptor antagonist also reached the fetus in low concentration. CONCLUSIONS: This suggests that minimal amount of maternally produced IL-1 family members cross the placental barrier. Their negative effects are likely indirect, through their deleterious placental actions.
Authors: Jenalee R Doom; Michelle Rozenman; Kathryn R Fox; Tiffany Phu; Anni R Subar; Deborah Seok; Kenia M Rivera Journal: Dev Psychopathol Date: 2021-12-07
Authors: Amanda M Vanderplow; Bailey A Kermath; Cassandra R Bernhardt; Kimberly T Gums; Erin N Seablom; Abigail B Radcliff; Andrea C Ewald; Mathew V Jones; Tracy L Baker; Jyoti J Watters; Michael E Cahill Journal: PLoS Biol Date: 2022-02-03 Impact factor: 8.029
Authors: M M Broadney; N Chahal; K A Michels; A C McLain; A Ghassabian; D A Lawrence; E H Yeung Journal: Int J Obes (Lond) Date: 2016-10-26 Impact factor: 5.095
Authors: Brahm Seymour Coler; Oksana Shynlova; Adam Boros-Rausch; Stephen Lye; Stephen McCartney; Kelycia B Leimert; Wendy Xu; Sylvain Chemtob; David Olson; Miranda Li; Emily Huebner; Anna Curtin; Alisa Kachikis; Leah Savitsky; Jonathan W Paul; Roger Smith; Kristina M Adams Waldorf Journal: J Clin Med Date: 2021-06-29 Impact factor: 4.241
Authors: Nicole R Bush; Lauren S Wakschlag; Kaja Z LeWinn; Irva Hertz-Picciotto; Sara S Nozadi; Sarah Pieper; Johnnye Lewis; Dominik Biezonski; Clancy Blair; Julianna Deardorff; Jenae M Neiderhiser; Leslie D Leve; Amy J Elliott; Cristiane S Duarte; Claudia Lugo-Candelas; T Michael O'Shea; Lyndsay A Avalos; Grier P Page; Jonathan Posner Journal: Front Psychiatry Date: 2020-06-19 Impact factor: 5.435